News | April 14, 2025
Novartis to invest $23 billion on expansion of manufacturing and R&D facilities in US
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
Expanded US manufacturing and R&D presence with investment in 10 facilities, including 7 brand new facilities
The National IP Awards recognize outstanding contributions to India’s innovation economy through effective IP creation and commercialization
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
The product will be launched in Q1FY26
The supply of these goods is set to commence within the first quarter of FY26
The company is targeting a Rs. 1,000 crore finished dosages business within the next five years
This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sharma brings a wealth of expertise in optimizing manufacturing processes for fermentation-based APIs and sterile injectables
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated
